逍遥散联合α干扰素治疗hbeag阳性慢性乙型肝炎的临床观察

《逍遥散联合α干扰素治疗hbeag阳性慢性乙型肝炎的临床观察》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、·666·中国中西医结合杂志2014年6月第34卷第6期CJITWM，June2014，Vol．34，No.6逍遥散联合α干扰素治疗HBeAg阳性慢性乙型肝炎的临床观察1112梁惠卿唐金模吴春城陈少东摘要目的研究逍遥散联合α干扰素(interferon-alpha，IFN-α)治疗HBeAg阳性慢性乙型肝炎疗效及对生活质量的影响。方法193例经肝穿刺活检证实的HBeAg阳性慢性乙型肝炎患者，按照随机数字表法分为单药治疗组(94例)和联合治疗组(99例)，单药治疗组给予IFN-α1b，50μg/次，皮

2、下注射，每周3次;联合治疗组在单药治疗组的基础上，配伍逍遥散口服，两组疗程均为24周。通过评价两组ALT复常率、HBeAg阴转率、HBeAg转换率、HBVDNA阴转率、完全应答率、部分应答率以及症状积分变化等观察逍遥散联合IFN-α疗效;采用慢性肝病问卷(chronicliverdiseasequestionnaire，CLDQ)评分进行生活质量评定;观察两组患者的不良反应发生率。结果联合治疗组在ALT复常率、HBeAg阴转率、HBVDNA阴转率、完全应答率、部分应答率、中医症状积分、中医症状总有效

3、率、CLDQ评分和不良反应发生率方面均优于单药治疗组(P＜0.05，P＜0.01)。结论逍遥散可提高IFN-α治疗HBeAg阳性慢性乙型肝炎的中医症状疗效、抗病毒疗效，改善生活质量，减少IFN-α不良反应。关键词慢性乙型肝炎;α干扰素;逍遥散;生活质量TreatmentofHBeAgPositiveChronicHepatitisBbyXiaoyaoPowderCombinedwithInterferon-α:aClinicalObserva-1112tionLIANGHui-qing，TANGJi

4、n-mo，WUChun-cheng，andCHENShao-dong1CenterforLiverDisease，Xia-menHospitalofTraditionalChineseMedicine，Fujian(361009)，China;2DepartmentofTraditionalChineseMedicine，Medi-calCollegeofXiamenUniversity，Fujian(361005)，ChinaABSTＲACTObjectiveTostudytheefficacyo

5、fXiaoyaoPowder(XYP)combinedwithinterferonalpha(IFN-α)intreatingHBeAgpositivechronichepatitisB(CHB)patientsandtheeffectontheirqualityoflife(QOL)．MethodsTotally193patientswithHBeAg-positiveCHBconfirmedbyliverbiopsywererandomlyassignedto2groups，GroupA(94c

6、ases)andGroupB(99cases)．IFN-α1bwassubcutaneouslyinjectedtopatientsinGroupAatthedoseof50μg，thriceperweek．ThoseinGroupBadditionallytookXYP．Thetherapeuticcourseforallwas24weeks．ClinicalefficacywasobservedbyassessingALTrestorationrate，HBeAgnega-tiverate，HB

7、eAgconversionrate，HBVDNAnegativerate，completeresponserate，partialresponserate，andsymptomsintegral．TheevaluationofQOLwasperformedbyusingchronicliverdiseasequestionnaire(CLDQ)score．Adversereactionoccurrenceratewasobservedinthetwogroups．ＲesultsBettereffec

8、tswereobtainedinGroupAonALTrestorationrate，HBeAgnegativerate，HBVDNAnegativerate，completeresponserate，partialresponserate，TCMsymptomsintegral，thetotaleffectiverateofTCMsysmptoms，CLDQscore，andadversereactionrates，showingstatisticaldiffere